Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 614 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total transaction of $27,556.32. Following the completion of the sale, the insider now directly owns 95,034 shares of the company's stock, valued at $4,265,125.92. This represents a 0.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Catriona Yale also recently made the following trade(s):
- On Tuesday, February 18th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $49.87, for a total transaction of $498,700.00.
- On Monday, December 16th, Catriona Yale sold 9,074 shares of Akero Therapeutics stock. The stock was sold at an average price of $29.11, for a total value of $264,144.14.
Akero Therapeutics Price Performance
Shares of Akero Therapeutics stock traded up $1.10 during midday trading on Monday, hitting $45.25. 224,398 shares of the company traded hands, compared to its average volume of 810,503. The firm's fifty day moving average price is $42.10 and its 200-day moving average price is $33.89. The stock has a market cap of $3.60 billion, a price-to-earnings ratio of -12.01 and a beta of -0.19. Akero Therapeutics, Inc. has a 12 month low of $17.86 and a 12 month high of $58.40. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its earnings results on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). As a group, sell-side analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on AKRO shares. HC Wainwright upped their target price on Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, March 3rd. Bank of America raised shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $35.00 to $63.00 in a research report on Thursday, January 30th. Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. UBS Group upped their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a report on Friday, January 31st. Finally, Citigroup increased their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $76.29.
View Our Latest Research Report on AKRO
Institutional Investors Weigh In On Akero Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in shares of Akero Therapeutics during the fourth quarter valued at about $41,000. Sterling Capital Management LLC boosted its position in Akero Therapeutics by 764.3% during the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock worth $50,000 after buying an additional 1,582 shares during the period. Quarry LP bought a new stake in Akero Therapeutics during the 4th quarter worth approximately $83,000. Summit Investment Advisors Inc. grew its holdings in Akero Therapeutics by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock worth $197,000 after acquiring an additional 450 shares during the last quarter. Finally, Summit Financial Wealth Advisors LLC acquired a new position in Akero Therapeutics in the 3rd quarter valued at approximately $205,000.
About Akero Therapeutics
(
Get Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
Read More
Before you consider Akero Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akero Therapeutics wasn't on the list.
While Akero Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
